Neurizon Therapeutics has locked in a $17.5 million R&D financing facility with Dare Capital, boosting its cash flow ahead of key HEALEY ALS trial milestones while reducing reliance on convertible notes.
- Up to $17.5 million facility secured against R&D Tax Incentive refunds
- Initial $8 million drawdown expected post-execution
- Non-dilutive funding supports HEALEY ALS Platform Trial
- Facility includes extension options for FY2027 and FY2028 claims
- Reduces near-term dependence on Obsidian convertible notes
Strategic R&D Financing to Strengthen Capital Position
Neurizon Therapeutics (ASX:NUZ) has secured a $17.5 million R&D financing facility with Dare Capital Loan Fund, marking a significant step in its capital management strategy. The facility is backed solely by the company’s anticipated R&D Tax Incentive refunds, providing a non-dilutive source of capital that aligns with Neurizon’s funding approach announced last December.
An initial drawdown of approximately $8 million is expected immediately following execution, corresponding to the estimated FY2026 R&D Tax Incentive refund. This upfront cash injection is designed to support ongoing investment in Neurizon’s pivotal Phase 2/3 HEALEY ALS Platform Trial, which is advancing toward topline data expected in Q2 2027.
Flexible Terms and Reduced Reliance on Convertible Notes
The loan carries an interest rate of 1.25% per month, capitalised monthly, with repayment triggered upon receipt of the government refund. The facility includes no establishment fee and offers annual extension options to cover Neurizon’s FY2027 and FY2028 R&D Tax Incentive claims, creating a multi-year funding runway.
This arrangement reduces Neurizon’s near-term dependence on its Obsidian convertible note facility, broadening its capital flexibility as it approaches key clinical milestones. The deal’s structure allows the company to draw down funds regularly against anticipated refunds, smoothing cash flow without diluting shareholders.
Specialist Partner Brings Expertise in Life Sciences Financing
Neurizon’s CFO Dan O’Connell highlighted the strategic nature of the partnership, praising Dare Capital’s specialist expertise in R&D financing for life sciences. He noted that the facility allows Neurizon to “bring forward non-dilutive capital earned through our investment in the HEALEY trial,” reinforcing the company’s financial position ahead of critical trial readouts.
Dare Capital’s focus on lending secured against Australian Government R&D Tax Incentive refunds makes it a fitting partner for Neurizon, which is navigating late-stage clinical development in a capital-intensive biotech sector.
Supporting Clinical Progress and Upcoming Milestones
The facility’s timing dovetails with Neurizon’s accelerated HEALEY ALS Platform Trial enrolment and progression. The trial recently expanded its cohort and is on track for topline efficacy and safety results by late Q2 2027, a milestone that will be critical for validating Neurizon’s lead drug candidate NUZ-001.
By securing this flexible, non-dilutive funding, Neurizon is better positioned to maintain clinical momentum without immediate pressure to raise equity or tap more expensive debt options. This financial manoeuvre could prove crucial as the company navigates the costly and uncertain path of late-stage neurodegenerative disease drug development.
Bottom Line?
Neurizon’s new R&D financing facility enhances its cash runway and funding flexibility, setting the stage for crucial HEALEY trial results without diluting shareholders.
Questions in the middle?
- How will the timing and amount of future R&D Tax Incentive refunds impact Neurizon’s drawdowns and cash flow?
- Will Neurizon extend the facility beyond FY2028 to support ongoing clinical development?
- How might this financing strategy influence Neurizon’s approach to potential equity raises or partnerships ahead of HEALEY trial data?